This Article Abstract Full Text (PDF) All Versions of this Article: 108/6/661    most recent 01.CIR.0000086981.09834.E0v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, Y. Articles by Rader, D. J. Search for Related Content PubMed PubMed Citation Articles by Zhang, Y. Articles by Rader, D. J. Pubmed/NCBI databases OMIM Compound via MeSH Substance via MeSH Hazardous Substances DB CHOLESTEROL TRITIUM Related Collections Lipid and lipoprotein metabolism

(Circulation. 2003;108:661.)
© 2003 American Heart Association, Inc.

Brief Rapid Communications

Overexpression of Apolipoprotein A-I Promotes Reverse Transport of Cholesterol From Macrophages to Feces In Vivo

YuZhen Zhang, MD, PhD^*; Ilaria Zanotti, PhD^*; Muredach P. Reilly, MD; Jane M. Glick, PhD; George H. Rothblat, PhD; Daniel J. Rader, MD

From the Departments of Medicine (Y.Z., M.R., D.J.R.) and Cell and Developmental Biology (J.M.G.) and the Center for Experimental Therapeutics (Y.Z., M.R., D.J.R.), University of Pennsylvania School of Medicine, Philadelphia, Pa; and the Children’s Hospital of Philadelphia (I.Z., G.H.R.), Philadelphia, Pa.

Correspondence to Daniel J. Rader, MD, University of Pennsylvania Medical Center, 654 Biomedical Research Building II/III, 421 Curie Blvd, Philadelphia, PA 19104. E-mail rader{at}mail.med.upenn.edu

Received March 11, 2003; revision received June 18, 2003; accepted June 19, 2003.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— Abundant data indicate that overexpression of apolipoprotein A-I (apoA-I) in mice inhibits atherosclerosis. One mechanism is believed to be promotion of reverse cholesterol transport, but no direct proof of this concept exists. We developed a novel approach to trace reverse transport of labeled cholesterol specifically from macrophages to the liver and feces in vivo and have applied this approach to investigate the ability of apoA-I overexpression to promote macrophage-specific reverse cholesterol transport.

Method and Results— J774 macrophages were loaded with cholesterol by incubation with acetylated LDL, labeled with ³H-cholesterol, and then injected intraperitoneally into mice. Plasma and feces were collected at 24 hours and 48 hours, when mice were exsanguinated, tissues were harvested, and all were analyzed for tracer counts. ³H-cholesterol was found in the plasma, liver, and feces. For apoA-I overexpression, mice were injected intravenously with apoA-I adenovirus (10¹¹ particles per animal) 3 days before labeled macrophages were injected. ApoA-I overexpression led to significantly higher ³H-cholesterol in plasma, liver, and feces. The amount of ³H-tracer in the liver was 35% higher (P<0.05) and the ³H-tracer excreted into feces over 48 hours was 63% higher (P<0.05) in apoA-I–expressing mice than in control mice.

Conclusion— Injection of ³H-cholesterol–labeled macrophage foam cells is a method of measuring reverse cholesterol transport specifically from macrophages to feces in vivo, and apoA-I overexpression promotes macrophage-specific reverse cholesterol transport.

Key Words: cholesterol • cholesterol, reverse transport • apolipoproteins • macrophages • atherosclerosis

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
There is a strong inverse association between plasma HDL cholesterol levels and incidence of atherosclerotic cardiovascular diseases. Apolipoprotein A-I (apoA-I) is the major protein in HDL and is synthesized and secreted by the intestine and the liver. Abundant data from studies in animals indicate that hepatic overexpression of apoA-I inhibits atherosclerosis,^1–4 but the mechanism(s) remain uncertain. ApoA-I is thought to protect against atherosclerosis at least in part by promoting efflux of excess cholesterol from macrophages in the arterial wall and returning that cholesterol to the liver for excretion into the bile, a process known as "reverse cholesterol transport."⁵ There have been various efforts to quantify reverse cholesterol transport in animals in response to changes in apoA-I levels. Stein et al⁶ reported no evidence of increased rate of loss of ³H-cholesterol from a muscle depot in human apoA-I–transgenic mice. Dietschy and colleagues reported that there was no difference in the rate of "net centripetal cholesterol flux" from the peripheral tissue under 2-fold difference in plasma apoA-I⁷ and that apoA-I–knockout mice were not different from wild-type mice with regard to peripheral cholesterol efflux.⁸ By measuring centripetal cholesterol flux and fecal sterol excretion, Spady and colleagues⁹ found no increase in reverse cholesterol transport in mice overexpressing apoA-I after injection of a recombinant adenoviral vector.

Therefore, despite continued enthusiasm for the concept of reverse cholesterol transport as a major mechanism by which apoA-I overexpression protects against atherosclerosis, no direct proof of this concept yet exists, which has created substantial doubt as to whether HDL and apoA-I actually promote the rate of reverse cholesterol transport.¹⁰ However, the methods used previously have estimated rates of reverse cholesterol transport from entire peripheral tissue and not specifically from macrophages, the most important cholesterol-accumulating cells in atherosclerosis. Macrophages are particularly reliant on the ABCA1 pathway, which is promoted by apoA-I, to rid themselves of excess cholesterol. We therefore developed a novel approach to measure reverse transport of labeled cholesterol specifically from macrophages to the liver and feces in vivo and have applied this approach to investigate the ability of apoA-I overexpression to promote macrophage-specific reverse cholesterol transport.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
J774 Cell Culture, ³H-Cholesterol Labeling, and Cholesterol Loading
J774 cells were obtained from American Type Culture Collection (ATCC; Manassas, Va) and were grown in suspension in RPMI 1640 supplemented with 10% fetal bovine serum. Cells were radiolabeled with 5µCi/mL ³H-cholesterol and cholesterol enriched with 100 µg/mL of acetylated LDL for 48 hours. These foam cells were washed twice, equilibrated in medium with 0.2% bovine serum albumin for 6 hours, spun down, and resuspended in 0.5 mL medium. The distribution of ³H-cholesterol between free cholesterol and cholesteryl ester in J774 cells was determined by thin-layer chromatography (TLC)¹¹. Cholesterol mass was determined by gas liquid chromatography (GLC).¹² The cholesterol content of J774 foam cells was markedly elevated, and the majority of cellular cholesterol was esterified. The distribution between free and esterified cholesterol was consistent in both TLC and GLC assays.

In Vivo Studies
Twenty male C57BL/6 mice (Jackson Laboratories, Bar Harbor, Me) were injected intravenously with recombinant adenoviral vector encoding human apoA-I (AdapoA-I, n=10)³ or a control adenovirus containing no transgene (Adnull, n=10) (10¹¹ particles per animal). Three days after vector injection, ³H-cholesterol–labeled J774 foam cells (7.8x10⁶ cells containing 3.8x10⁶ counts per minute [cpm] in 0.5 mL minimum essential medium) were injected intraperitoneally. Blood was collected at 24 hours (retro-orbital plexus) and 48 hours (vena cava), and plasma was used for liquid scintillation counting and lipoprotein analysis. Feces were collected continuously from 0 to 24 hours and 24 hours to 48 hours and were stored at -20°C until extraction of cholesterol and bile acid. At 48 hours, mice were anesthetized, and the vasculature was perfused with cold phosphate-buffered saline. Liver, spleen, and lungs were removed and stored at -20°C until lipid extraction. An additional apoA-I overexpression experiment was performed in C57BL/6 female mice (n=8; Jackson Laboratories).

Fecal Cholesterol and Bile Acid Extraction
Fecal cholesterol and bile acid were extracted as described previously.¹³ The levels are expressed as counts per minute in total feces by wet weight.

Tissue Lipid Extraction
Tissue lipids were extracted using the method of Bligh and Dyer¹⁴ and expressed as counts per minute in total organ. The distribution of cholesterol between free and esterified forms in liver, spleen, and lung were measured by both TLC¹¹ and GLC.¹²

Plasma Lipid Analysis
Plasma total cholesterol, HDL cholesterol, phospholipid, and human apoA-I levels were measured on a Cobas Fara (Roche Diagnostics Systems, Inc) using Sigma Diagnostics reagents as described previously,¹⁵ and the levels were expressed as milligrams per liter. Serum lipoproteins were isolated by ultracentrifugation¹⁶ and analyzed for the distribution of ³H-cholesterol among lipoprotein fractions.

Statistical Analysis
Values are presented as mean±SEM. Results were analyzed by ANOVA and Student’s t test with the use of GraphPad Prism Software.

	Results

Top Abstract Introduction Methods Results Discussion References

 
A pilot experiment using 4 male and 4 female C57BL/6 mice demonstrated the feasibility of measuring reverse cholesterol transport after the injection of macrophage foam cells containing ³H-cholesterol. Data on the flux of radiolabeled cholesterol in the pilot study are not shown but were essentially identical to those presented for the control animals in the apoA-I overexpression experiment shown here. Male mice overexpressing apoA-I, compared with control mice, had significantly higher plasma levels of apoA-I (26.8 versus 0.4 mg/L), total cholesterol (16 versus 7.9 mg/L), HDL cholesterol (11.4 versus 5.5 mg/L), and phospholipids (24.6 versus 16.8 mg/L). The plasma ³H-cholesterol levels at both 24 and 48 hours were significantly higher in the mice injected with apoA-I adenovirus compared with control mice (Figure 1A), were primarily in the HDL fraction, and were correlated with plasma apoA-I levels at 24 hours (r=0.65, P<0.05) and at 48 hours (r=0.62, P<0.05). The mice expressing apoA-I had 35% higher ³H-tracer in liver (P<0.05) and excreted 63% more ³H-tracer into feces (P<0.05) over 48 hours than did control mice (Figure 1B). The ³H-tracer detected in the fecal bile acid was similar in both apoA-I–overexpressing mice and control mice at 24 hours and 48 hours (Figure 2). In a separate experiment, overexpression of apoA-I in female mice resulted in increases in ³H tracer in plasma, tissues, and feces similar to those observed in the male mice (data not shown).

View larger version (38K): [in this window] [in a new window]   Figure 1. C57BL/6 mice were injected intravenously with apoA-I adenovirus (n=10) or control (null) adenovirus vector (n=10) (1.0x1011 particles of each virus per animal). Three days after vector injection, 3H-cholesterol–labeled J774 foam cells were injected (7.8x106 J774 cells containing 3.8x106 cpm 3H-cholesterol in 0.5 mL medium). A, 3H-tracer in plasma at 24 and 48 hours. B, 3H-tracer in tissue and feces.

View larger version (20K): [in this window] [in a new window]   Figure 2. 3H-cholesterol and 3H-bile acids in feces at 24 hours and 48 hours after overexpression of apoA-I in mice injected with 3H-cholesterol–labeled J774 foam cells.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
We report the development of a novel approach for tracing reverse transport of radiolabeled cholesterol specifically from macrophages to the liver and feces in vivo. After intraperitoneal injection of ³H-cholesterol–labeled macrophage foam cells, ³H-cholesterol was detected in plasma, lung, spleen, liver, and feces. Furthermore, a substantial fraction of the tracer in feces was found in bile acids, indicating conversion of ³H-cholesterol into ³H-bile acid in the liver. These results demonstrate that ³H-cholesterol originating in cholesterol-loaded macrophages was transported through the plasma to the liver, converted in part into bile acids, and then excreted as either free cholesterol or bile acid into bile and ultimately into the feces. Mice overexpressing apoA-I had significantly higher plasma ³H-cholesterol and higher ³H-tracer in the liver and excreted 63% more ³H-tracer into feces over 48 hours than did control mice.

Although we cannot fully rule out the migration of intact macrophages from the peritoneum to the liver, an examination of the distribution of ³H-cholesterol between free and esterified pools speaks against this. In our pilot experiment, we measured the distribution of free and esterified cholesterol in ³H-cholesterol–labeled J774 foam cells and in mouse liver, spleen, and lung by TLC and also determined their masses of free and esterified cholesterol. The majority of cellular cholesterol of labeled J774 foam cells was esterified (70%), whereas 15%, 13%, and 11% of the ³H-cholesterol in the liver, spleen, and lung was esterified. This suggests that the ³H-sterol in tissues was not transported there by macrophages. The abundant ³H-cholesterol detected in plasma and the fact that 75% of the tracer in plasma was in the HDL fraction suggests a model in which ³H-cholesterol was available for efflux from macrophages in situ and was transported through the plasma compartment to the liver, mainly on HDL particles.

It has been widely assumed that apoA-I overexpression inhibits atherosclerosis at least in part by reverse cholesterol transport. However, data proving this have been lacking, raising the question as to whether apoA-I overexpression actually promotes the rate of reverse cholesterol transport. The methods used previously have estimated rates of reverse cholesterol transport from entire peripheral tissue and not specifically from macrophages. Our studies demonstrate for the first time that apoA-I overexpression promotes macrophage-specific reverse cholesterol transport in vivo. It is possible that macrophages are more responsive to increases in plasma concentrations of apoA-I than are other cell types, and this tracer approach may allow more effective measurement of reverse cholesterol transport than mass-based approaches.

In summary, we report the development of a novel approach for tracing reverse transport of labeled cholesterol specifically from macrophages to the liver and feces in vivo. Using this approach, we demonstrate for the first time that apoA-I overexpression promotes macrophage-specific reverse cholesterol transport in vivo. This method may be applied to other questions about the roles of specific genes in regulating the rate of reverse cholesterol transport.

	Acknowledgments

 
This study was funded in part by grants RO1-HL55323, P01-HL59407, P50-HL70128, P01-HL22633 and RO1-HL63768 from the National Heart, Lung and Blood Institute. Dr Rader is an Established Investigator of the American Heart Association, a recipient of a Burroughs Wellcome Foundation Clinical Scientist Award in Translational Research, and a recipient of a Doris Duke Distinguished Clinical Scientist Award. We are indebted to Anthony Secreto, Dawn Marchadier, Anna Lillethun, and Linda Morrell for expert technical assistance.

	Footnotes

 
*These two authors contributed equally to this manuscript.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Rubin E, Krauss R, Spangler E, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991; 353: 265–267.[CrossRef][Medline] [Order article via Infotrieve]
   
2. Plump A, Scott C, Breslow J. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E–deficient mouse. Proc Natl Acad Sci U S A. 1994; 91: 9607–9611.[Abstract/Free Full Text]
   
3. Tangirala RK, Tsukamoto K, Chun SH, et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 1999; 100: 1816–1822.[Abstract/Free Full Text]
   
4. Duverger N, Kruth H, Emmanuel F, et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I–transgenic rabbits. Circulation. 1996; 94: 713–717.[Abstract/Free Full Text]
   
5. Barter PJ, Rye K. Molecular mechanisms of reverse cholesterol transport. Curr Opin Lipidol. 1996; 7: 82–87.[Medline] [Order article via Infotrieve]
   
6. Stein O, Dabach Y, Hollander G, et al. High levels of human apolipoprotein A-I and high density lipoproteins in transgenic mice do not enhance efflux of cholesterol from a depot of injected lipoproteins. Atherosclerosis. 1999; 144: 367–374.[CrossRef][Medline] [Order article via Infotrieve]
   
7. Osono Y, Woollett LA, Marotti KR, et al. Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma. Proc Natl Acad Sci U S A. 1996; 93: 4114–4119.[Abstract/Free Full Text]
   
8. Jolley CD, Woollett LA, Turley SD, et al. Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration. J Lipid Res. 1998; 39: 2143–2149.[Abstract/Free Full Text]
   
9. Alam K, Meidell RS, Spady DK. Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. J Biol Chem. 2001; 276: 15641–15649.[Abstract/Free Full Text]
   
10. Tall AR, Wang N, Mucksavage P. Is it time to modify the reverse cholesterol transport model? J Clin Invest. 2001; 108: 1273–1275.[CrossRef][Medline] [Order article via Infotrieve]
    
11. Kellner-Weibel G, Jerome WG, Small DM, et al. Effects of intracellular free cholesterol accumulation on macrophage viability: a model for foam cell death. Arterioscler Thromb Vasc Biol. 1998; 18: 423–431.[Abstract/Free Full Text]
    
12. Klansek JJ, Yancey P, St Clair RW, et al. Cholesterol quantitation by GLC: artifactual formation of short-chain steryl esters. J Lipid Res. 1995; 36: 2243–2250.[Abstract]
    
13. Batta AK, Salen G, Rapole KR, et al. Highly simplified method for gas-liquid chromatographic quantitation of bile acids and sterols in human stool. J Lipid Res. 1999; 40: 1148–1154.[Abstract/Free Full Text]
    
14. Iverson SJ, Lang SL, Cooper MH. Comparison of the Bligh and Dyer and Folch methods for total lipid determination in a broad range of marine tissue. Lipids. 2001; 36: 1283–1287.[Medline] [Order article via Infotrieve]
    
15. Tietge UJ, Maugeais C, Lund-Katz S, et al. Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. Arterioscler Thromb Vasc Biol. 2002; 22: 1213–1218.[Abstract/Free Full Text]
    
16. Millar JS, Lichtenstein AH, Ordovas JM, et al. Human triglyceride-rich lipoprotein apo E kinetics and its relationship to LDL apo B-100 metabolism. Atherosclerosis. 2001; 155: 477–485.[CrossRef][Medline] [Order article via Infotrieve]
    

This article has been cited by other articles:

				E. Sehayek and S. L. Hazen Cholesterol Absorption From the Intestine Is a Major Determinant of Reverse Cholesterol Transport From Peripheral Tissue Macrophages Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1296 - 1297. [Abstract] [Full Text] [PDF]

				E. M. deGoma, R. L. deGoma, and D. J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2199 - 2211. [Abstract] [Full Text] [PDF]

				I. Zanotti, F. Poti, M. Pedrelli, E. Favari, E. Moleri, G. Franceschini, L. Calabresi, and F. Bernini The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential J. Lipid Res., May 1, 2008; 49(5): 954 - 960. [Abstract] [Full Text] [PDF]

				J. A. Araujo, B. Barajas, M. Kleinman, X. Wang, B. J. Bennett, K. W. Gong, M. Navab, J. Harkema, C. Sioutas, A. J. Lusis, et al. Ambient Particulate Pollutants in the Ultrafine Range Promote Early Atherosclerosis and Systemic Oxidative Stress Circ. Res., March 14, 2008; 102(5): 589 - 596. [Abstract] [Full Text] [PDF]

				J. S. Troutt, W. E. Alborn, M. K. Mosior, J. Dai, A. T. Murphy, T. P. Beyer, Y. Zhang, G. Cao, and R. J. Konrad An apolipoprotein A-I mimetic dose-dependently increases the formation of pre{beta}1 HDL in human plasma J. Lipid Res., March 1, 2008; 49(3): 581 - 587. [Abstract] [Full Text] [PDF]

				U. Tchoua, W. D'Souza, N. Mukhamedova, D. Blum, E. Niesor, J. Mizrahi, C. Maugeais, and D. Sviridov The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport Cardiovasc Res, March 1, 2008; 77(4): 732 - 739. [Abstract] [Full Text] [PDF]

				Y. Levy High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench Cardiovasc Res, March 1, 2008; 77(4): 614 - 615. [Full Text] [PDF]

				M. P. Adorni, F. Zimetti, J. T. Billheimer, N. Wang, D. J. Rader, M. C. Phillips, and G. H. Rothblat The roles of different pathways in the release of cholesterol from macrophages J. Lipid Res., November 1, 2007; 48(11): 2453 - 2462. [Abstract] [Full Text] [PDF]

				M. Kockx, D. L. Guo, T. Huby, P. Lesnik, J. Kay, T. Sabaretnam, E. Jary, M. Hill, K. Gaus, J. Chapman, et al. Secretion of Apolipoprotein E From Macrophages Occurs via a Protein Kinase A and Calcium-Dependent Pathway Along the Microtubule Network Circ. Res., September 14, 2007; 101(6): 607 - 616. [Abstract] [Full Text] [PDF]

				H. Tanigawa, J. T. Billheimer, J.-i. Tohyama, Y. Zhang, G. Rothblat, and D. J. Rader Expression of Cholesteryl Ester Transfer Protein in Mice Promotes Macrophage Reverse Cholesterol Transport Circulation, September 11, 2007; 116(11): 1267 - 1273. [Abstract] [Full Text] [PDF]

				M.-D. Wang, V. Franklin, and Y. L. Marcel In Vivo Reverse Cholesterol Transport From Macrophages Lacking ABCA1 Expression Is Impaired Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1837 - 1842. [Abstract] [Full Text] [PDF]

				R. Asleh, R. Miller-Lotan, M. Aviram, T. Hayek, M. Yulish, J. E. Levy, B. Miller, S. Blum, U. Milman, C. Shapira, et al. Haptoglobin Genotype Is a Regulator of Reverse Cholesterol Transport in Diabetes In Vitro and In Vivo Circ. Res., December 8, 2006; 99(12): 1419 - 1425. [Abstract] [Full Text] [PDF]

				A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]

				S. Rashid, B. W. Patterson, and G. F. Lewis Thematic review series: Patient-Oriented Research. What have we learned about HDL metabolism from kinetics studies in humans? J. Lipid Res., August 1, 2006; 47(8): 1631 - 1642. [Abstract] [Full Text] [PDF]

				C. Y. Han, T. Chiba, J. S. Campbell, N. Fausto, M. Chaisson, G. Orasanu, J. Plutzky, and A. Chait Reciprocal and Coordinate Regulation of Serum Amyloid A Versus Apolipoprotein A-I and Paraoxonase-1 by Inflammation in Murine Hepatocytes Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1806 - 1813. [Abstract] [Full Text] [PDF]

				O. Zschenker, T. Illies, and D. Ameis Overexpression of lysosomal Acid lipase and other proteins in atherosclerosis. J. Biochem., July 1, 2006; 140(1): 23 - 38. [Abstract] [Full Text] [PDF]

				M. Cuchel and D. J. Rader Macrophage Reverse Cholesterol Transport: Key to the Regression of Atherosclerosis? Circulation, May 30, 2006; 113(21): 2548 - 2555. [Full Text] [PDF]

				C. Tso, G. Martinic, W.-H. Fan, C. Rogers, K.-A. Rye, and P. J. Barter High-Density Lipoproteins Enhance Progenitor-Mediated Endothelium Repair in Mice Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 1144 - 1149. [Abstract] [Full Text] [PDF]

				A. H.E.M. Klerkx, K. E. Harchaoui, W. A. van der Steeg, S. M. Boekholdt, E. S.G. Stroes, J. J.P. Kastelein, and J. A. Kuivenhoven Cholesteryl Ester Transfer Protein (CETP) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels: Pathways by Which Modulation of CETP Activity May Alter Atherogenesis Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 706 - 715. [Abstract] [Full Text] [PDF]

				D. Duffy and D. J. Rader Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport Circulation, February 28, 2006; 113(8): 1140 - 1150. [Full Text] [PDF]

				S. U. Naik, X. Wang, J. S. Da Silva, M. Jaye, C. H. Macphee, M. P. Reilly, J. T. Billheimer, G. H. Rothblat, and D. J. Rader Pharmacological Activation of Liver X Receptors Promotes Reverse Cholesterol Transport In Vivo Circulation, January 3, 2006; 113(1): 90 - 97. [Abstract] [Full Text] [PDF]

				R. E. Moore, M. Navab, J. S. Millar, F. Zimetti, S. Hama, G. H. Rothblat, and D. J. Rader Increased Atherosclerosis in Mice Lacking Apolipoprotein A-I Attributable to Both Impaired Reverse Cholesterol Transport and Increased Inflammation Circ. Res., October 14, 2005; 97(8): 763 - 771. [Abstract] [Full Text] [PDF]

				D.-Q. Peng, Z. Wu, G. Brubaker, L. Zheng, M. Settle, E. Gross, M. Kinter, S. L. Hazen, and J. D. Smith Tyrosine Modification Is Not Required for Myeloperoxidase-induced Loss of Apolipoprotein A-I Functional Activities J. Biol. Chem., October 7, 2005; 280(40): 33775 - 33784. [Abstract] [Full Text] [PDF]

				V. Fuster, P. R. Moreno, Z. A. Fayad, R. Corti, and J. J. Badimon Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts J. Am. Coll. Cardiol., September 20, 2005; 46(6): 937 - 954. [Abstract] [Full Text] [PDF]

				M. Navab, G.M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, J. S. Frank, V. R. Grijalva, V. K. Ganesh, V. K. Mishra, M. N. Palgunachari, et al. Oral Small Peptides Render HDL Antiinflammatory in Mice and Monkeys and Reduce Atherosclerosis in ApoE Null Mice Circ. Res., September 16, 2005; 97(6): 524 - 532. [Abstract] [Full Text] [PDF]

				N. Rotllan, V. Ribas, L. Calpe-Berdiel, J. M. Martin-Campos, F. Blanco-Vaca, and J. C. Escola-Gil Overexpression of Human Apolipoprotein A-II in Transgenic Mice Does Not Impair Macrophage-Specific Reverse Cholesterol Transport In Vivo Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): e128 - e132. [Abstract] [Full Text] [PDF]

				M. Navab, G.M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, V. R. Grijalva, N. Yu, B. J. Ansell, G. Datta, D. W. Garber, et al. Apolipoprotein A-I Mimetic Peptides Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1325 - 1331. [Abstract] [Full Text] [PDF]

				G. F. Lewis and D. J. Rader New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport Circ. Res., June 24, 2005; 96(12): 1221 - 1232. [Abstract] [Full Text] [PDF]

				G. Escher, A. Hoang, S. Georges, U. Tchoua, A. El-Osta, Z. Krozowski, and D. Sviridov Demethylation using the epigenetic modifier, 5-azacytidine, increases the efficiency of transient transfection of macrophages J. Lipid Res., February 1, 2005; 46(2): 356 - 365. [Abstract] [Full Text] [PDF]

				P. J. Barter, S. Nicholls, K.-A. Rye, G.M. Anantharamaiah, M. Navab, and A. M. Fogelman Antiinflammatory Properties of HDL Circ. Res., October 15, 2004; 95(8): 764 - 772. [Abstract] [Full Text] [PDF]

				M. Navab, G.M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, V. R. Grijalva, A. C. Wagner, J. S. Frank, G. Datta, D. Garber, et al. Oral D-4F Causes Formation of Pre-{beta} High-Density Lipoprotein and Improves High-Density Lipoprotein-Mediated Cholesterol Efflux and Reverse Cholesterol Transport From Macrophages in Apolipoprotein E-Null Mice Circulation, June 29, 2004; 109(25): 3215 - 3220. [Abstract] [Full Text] [PDF]

				M. Navab, G. M. Ananthramaiah, S. T. Reddy, B. J. Van Lenten, B. J. Ansell, G. C. Fonarow, K. Vahabzadeh, S. Hama, G. Hough, N. Kamranpour, et al. Thematic review series: The Pathogenesis of Atherosclerosis The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL J. Lipid Res., June 1, 2004; 45(6): 993 - 1007. [Abstract] [Full Text] [PDF]

				D. J. Rader High-Density Lipoproteins as an Emerging Therapeutic Target for Atherosclerosis JAMA, November 5, 2003; 290(17): 2322 - 2324. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 108/6/661    most recent 01.CIR.0000086981.09834.E0v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal <